Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 687 across all filing types
Latest filing 2022-01-17 Regulatory Filings
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Positive Safety Data from Second Cohort of PI Clinical Trial 3 pages 277.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement reporting positive safety data from a Phase I clinical trial of a pharmaceutical product (RECCE 327). It provides details about the clinical trial cohorts, dosing, safety outcomes, and future trial plans. There is no indication that this is a full financial report, audit report, earnings release, or any other financial filing. The content is a corporate announcement related to clinical trial progress and safety data, typical of a regulatory or general announcement to the market. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2022-01-17 English
Positive Safety Data from Phase 1 Clinical Trial 3 pages 318.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement reporting positive safety data from the first cohort of a Phase I clinical trial for a pharmaceutical product. It includes details about the clinical trial progress, dosing cohorts, and safety outcomes. There is no indication that this is a full financial report, audit report, or regulatory filing. It is a specific update on clinical trial results, which is typical of a Capital/Financing Update or general company progress announcement. Given the nature of the content focusing on clinical trial progress and safety data, and the fact it is an official announcement by the company, the most appropriate classification is Capital/Financing Update (CAP). The document length is 4607 characters, which is consistent with an announcement rather than a full report. Confidence is high due to clear clinical trial update context and no financial statements or regulatory certifications present.
2022-01-06 English
Patients to be Dosed in Ph 1 IV Clinical Trial of R327 2 pages 254.4KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement about the commencement of dosing in a Phase I clinical trial for a pharmaceutical product. It provides highlights, trial details, and company background. There are no financial statements, regulatory certifications, or detailed financial data. The document is relatively short (4087 characters) and serves as a news update rather than a detailed report or filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings related to financial or governance matters. It is best classified as a general regulatory announcement about clinical trial progress, which fits under Regulatory Filings (RNS) as a fallback category for miscellaneous announcements that do not fit other specific categories.
2021-12-14 English
Update on Phase I/II Clinical Trial for Burn Wound Infection 3 pages 281.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement providing an update on a Phase I/II clinical trial for a pharmaceutical treatment. It includes clinical trial progress, patient outcomes, and statements from company executives. There are no financial statements, regulatory certifications, or detailed financial data. The content is focused on clinical trial progress and company updates rather than financial results or governance. The document length is 5635 characters, which is relatively short and typical for an announcement rather than a full report. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or certification. The best fit is a general regulatory announcement about clinical trial progress, which falls under Regulatory Filings (RNS).
2021-12-06 English
AGM Presentation 11 pages 2.2MB
AGM Information Classification · 95% confidence The document is titled 'Annual General Meeting' and dated 22 November 2021. It contains a presentation format with disclaimers, a summary of announcements since the last AGM, detailed descriptions of clinical trials, corporate updates, and capital structure information. The content is typical of materials shared during an AGM to inform shareholders about company progress, clinical developments, and corporate matters. There are no full financial statements or detailed financial performance data that would indicate an Annual Report (10-K) or Interim Report (IR). It is not a transcript of a call, nor an audit or legal report. The document is a presentation prepared for the Annual General Meeting, consistent with the AGM Information category (AGM-R). The document length (12,108 characters) supports it being a full presentation rather than a brief announcement. Therefore, the classification is AGM Information (AGM-R) with high confidence.
2021-11-21 English
Results of Meeting 2 pages 185.1KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 22 November 2021 reporting the results of the 2021 Annual General Meeting (AGM) of Recce Pharmaceuticals Limited. It details the voting outcomes on various resolutions, including adoption of the remuneration report, re-election of directors, and approvals related to share issues. The document explicitly states it is the "Results of 2021 Annual General Meeting" and provides detailed proxy vote counts and poll results. The content is focused on the official announcement of voting results from the AGM, not the AGM materials themselves or the full annual report. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and it is a formal announcement of voting results, not the full report or presentation from the AGM.
2021-11-21 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.